Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients

  • Authors:
    • Camillo Porta
    • Ilaria Imarisio
    • Mara De Amici
    • Lucia Bonomi
    • Chiara Paglino
    • Elisa Biscaldi
    • Matteo Zimatore
    • Andrea Sartore-Bianchi
    • Marco Danova
    • Remigio Moratti
    • Alberto Riccardi
  • View Affiliations

  • Published online on: April 1, 2005     https://doi.org/10.3892/or.13.4.689
  • Pages: 689-695
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Using a commercial ELISA assay, we evaluated circulating VEGF and bFGF levels in 203 consecutive patients with solid tumors, and sought a correlation between them and with the grade of anemia. Serum VEGF values were within the normal range in 128 patients (63.05%), with a mean value of 675.04 pg/ml (median, 571.00; range, 0-2796.54). The analysis of VEGF values per tumor group did not provide any statistically significant difference. Regarding bFGF, 143 patients (70.44%) had measurable, and thus abnormal, bFGF values. Overall, mean bFGF serum value was 57.14 pg/ml (median, 8.30; range, 0-4334.71), with the highest bFGF levels found in breast carcinoma patients. As expected, a large number of our patients was fairly anemic, mean hemoglobin level being 11.47 g/dl (median, 11.30; range, 7.1-19.20), the lowest titers being observed in prostate carcinoma patients. No statistically significant correlation was found between serum VEGF and hemoglobin values (r=0.004) but a significant negative correlation was seen between serum bFGF and hemoglobin (r=-0.22, p<0.05). Considering the different tumor groups, a statistically significant negative correlation between bFGF and hemoglobin becomes even more apparent in the subgroup of renal carcinoma patients (r=-0.55, p<0.05). In conclusion, our results demonstrate that there is a statistically significant correlation between systemic hypoxia (evaluated in terms of hemoglobin levels) and circulating bFGF values, but not VEGF; this correlation may lead to therapeutic interventions.

Related Articles

Journal Cover

April 2005
Volume 13 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Porta C, Imarisio I, De Amici M, Bonomi L, Paglino C, Biscaldi E, Zimatore M, Sartore-Bianchi A, Danova M, Moratti R, Moratti R, et al: Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. Oncol Rep 13: 689-695, 2005.
APA
Porta, C., Imarisio, I., De Amici, M., Bonomi, L., Paglino, C., Biscaldi, E. ... Riccardi, A. (2005). Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. Oncology Reports, 13, 689-695. https://doi.org/10.3892/or.13.4.689
MLA
Porta, C., Imarisio, I., De Amici, M., Bonomi, L., Paglino, C., Biscaldi, E., Zimatore, M., Sartore-Bianchi, A., Danova, M., Moratti, R., Riccardi, A."Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients". Oncology Reports 13.4 (2005): 689-695.
Chicago
Porta, C., Imarisio, I., De Amici, M., Bonomi, L., Paglino, C., Biscaldi, E., Zimatore, M., Sartore-Bianchi, A., Danova, M., Moratti, R., Riccardi, A."Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients". Oncology Reports 13, no. 4 (2005): 689-695. https://doi.org/10.3892/or.13.4.689